Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis

Bibliography

• WHO Hepatitis B Fact Sheet [Internet]. 2012. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ, Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• de Jongh FE, Janssen HL, de Man RA, Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5
   PubMed Web of Science ®Google Scholar
• Chen C-J, Iloeje UH, Yang H-I. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007;11:797-816; viii
   PubMedGoogle Scholar
• Iloeje UH, Yang H-I, Chen C-J. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012;32:1333-41
   PubMed Web of Science ®Google Scholar
• Peng C-Y, Chien R-N, Liaw Y-F. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-50
   PubMed Web of Science ®Google Scholar
• Chang T-T, Liaw Y-F, Wu S-S, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
   PubMed Web of Science ®Google Scholar
• Cho Y, Lee DH, Chung KH, The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci 2012. [Epub ahead of print]
   Google Scholar
• Yip B, Chaung K, Wong CR, Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012;57:3011-16
   PubMedGoogle Scholar
• Shim JH, Lee HC, Kim KM, Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Sheen I-S, Lee C-M, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
   PubMed Web of Science ®Google Scholar
• Schiff E, Simsek H, Lee WM, Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103:2776-83
   PubMed Web of Science ®Google Scholar
• Hsu Y-C, Mo L-R, Chang C-Y, Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther (Lond.) 2012;17:605-12
   PubMed Web of Science ®Google Scholar
• Hyun JJ, Seo YS, Yoon E, Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012;32:656-64
   PubMedGoogle Scholar
• Koklu S, Tuna Y, Gulsen MT, Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2012;11:88-94
   PubMedGoogle Scholar
• Marcellin P, Buti M, Gane EJ, Six years of treatment with tenofovir DF for chronic hepatitis b virus infection is and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2012;56(4 Suppl):374A-5A
   Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• Coffin CS, Fung SK, Ma M. Management of chronic hepatitis B: canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38
   PubMedGoogle Scholar
• Liaw Y-F, Kao J-H, Piratvisuth T, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61
   PubMed Web of Science ®Google Scholar
• Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-89
   PubMed Web of Science ®Google Scholar
• Zoutendijk R, Reijnders JGP, Zoulim F, Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Marcellin P, Gane E, Buti M, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
   PubMed Web of Science ®Google Scholar
• Chang T-T, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
   PubMed Web of Science ®Google Scholar
• Yamanaka G, Wilson T, Innaimo S, Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3
   PubMed Web of Science ®Google Scholar
• Innaimo SF, Seifer M, Bisacchi GS, Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8
   PubMed Web of Science ®Google Scholar
• Price PM, Banerjee R, Jeffrey AM, The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology 1992;16:8-12
   PubMed Web of Science ®Google Scholar
• Levine S, Hernandez D, Yamanaka G, Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002;46:2525-32
   PubMed Web of Science ®Google Scholar
• Baraclude Product Monograph. 2010
   Google Scholar
• Yan J-H, Bifano M, Olsen S, Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006;46:1250-8
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Lee GH, Aung MO, Dan YY, Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol 2013;85:26-33
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WP, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang T-T, Lim SGL, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Woodward CLN, Hall AM, Williams IG, Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-7
   PubMed Web of Science ®Google Scholar
• FDA Baraclude Prescribing Information
   Google Scholar
• Peignoux MM, Lapalus M, Asselah T. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013
   Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-29
   PubMed Web of Science ®Google Scholar